Anthracyclines‐containing regimens for treatment of follicular lymphoma in adults
Referencias
Additional references
Bartlett NL, Rizeq M, Dorfman RF, Halpern J, Horning SJ. Follicular large‐cell lymphoma: intermediate or low grade?. Journal of Clinical Oncology 1994;12(7):1349‐57.
Bendandi M. Aiming at a curative strategy for follicular lymphoma. CA: A Cancer Journal for Clinicians 2008;58(5):305‐17.
Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treatments Reports 1978;62(6):865‐72.
Brandt L, Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in indolent non‐Hodgkin's lymphoma. Acta Oncologica 2001;40(2‐3):213‐23.
Buske C, Gisselbrecht C, Gribben J, Letai T, McLaughlin P, Wilson W. Refining the treatment of follicular lymphoma. Leukemia & Lymphoma 2008;49 Suppl 1:18‐26.
Chau I, Jones R, Cunningham D, Wotherspoon A, Maisey N, Norman AR, et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front‐line therapy?. British Journal of Cancer 2003;89(1):36‐42.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non‐Hodgkin’s lymphomas. Journal of Clinical Oncology 1999;17(4):1244‐53.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology 2007;25(5):579‐86.
Coiffier B, Neidhardt‐Berard EM, Tilly H, Belanger C, Bouabdallah R, Haioun C, et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Annals of Oncology 1999;10(10):1191‐7.
Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, et al. Long‐term follow‐up of patients with low‐grade malignant lymphomas treated with doxorubicin‐based chemotherapy or chemoimmunotherapy. Journal of Clinical Oncology 1993;11(4):644‐51.
Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000;95(3):783‐9.
Federico M, Bellei M, Marcheselli L, Luminari S, Lopez‐Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Journal of Clinical Oncology 2009;27(27):4555‐62.
Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. Journal of Clinical Oncology 2009;27(8):1202‐8.
Ganti AK, Weisenburger DD, Smith LM, Hans CP, Bociek RG, Bierman PJ, et al. Patients with grade 3 follicular lymphoma have prolonged relapse‐free survival following anthracycline‐based chemotherapy: the Nebraska Lymphoma Study Group Experience. Annals of Oncology 2006;17(6):920‐7.
Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw‐Hill, 2006.
Greb A, Bohlius J, Schiefer D, Schwarzer G, Schulz H, Engert A. High‐dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non‐Hodgkin lymphoma (NHL) in adults. Cochrane Database of Systematic Reviews 2008, Issue 1. [Art. No.: CD004024. DOI: 10.1002/14651858.CD004024.pub2]
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European‐American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84(5):1361‐92.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Horning SJ, Rosenberg SA. The natural history of initially untreated low‐grade non‐Hodgkin's lymphomas. New England Journal of Medicine 1984;311(23):1471‐5.
Lister TA, Cullen MH, Beard ME, Brearley RL, Whitehouse JM, Wrigley PF, et al. Comparison of combined and single‐agent chemotherapy in non‐Hodgkin's lymphoma of favourable histological type. British Medical Journal 1978;1(6112):533‐7.
Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, et al. Improvement of overall and failure‐free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. Journal of Clinical Oncology 2006;24(10):1582‐9.
Mann RB, Berard CW. Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematology and Oncology 1983;1(2):187‐92.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47(1):207‐14.
Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B‐cell lymphoma. Journal of Clinical Oncology 2007;25(17):2426‐33.
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992‐2001. Blood 2006;107(1):265‐76.
NHLCP. A clinical evaluation of the International Lymphoma Study Group classification of non‐Hodgkin's lymphoma. The Non‐Hodgkin's Lymphoma Classification Project. Blood 1997;89(11):3909‐18.
Outomuro D, Grana DR, Azzato F, Milei J. Adriamycin‐induced myocardial toxicity: new solutions for an old problem?. International Journal of Cardiology 2007;117(1):6‐15.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815‐34.
Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, et al. Prolonged single‐agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology 2003;21(1):5‐15.
Rigacci L, Federico M, Martelli M, Zinzani PL, Cavanna L, Bellesi G, et al. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leukemia & Lymphoma 2003;44(11):1911‐7.
Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, et al. Chemotherapy plus rituximab versus chemotherapy alone for B‐cell non‐Hodgkin's lymphoma. Cochrane Database of Systematic Reviews 2007, Issue 4. [Art. No.: CD003805. DOI: 10.1002/14651858.CD003805.pub2]
Siddhartha G, Vijay P. R‐CHOP versus R‐CVP in the treatment of follicular lymphoma: a meta‐analysis and critical appraisal of current literature. Journal of Hematology and Oncology 2009;2:14.
Solal‐Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, et al. Recombinant interferon alfa‐2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. New England Journal of Medicine 1993;329(22):1608‐14.
Solal‐Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz‐Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104(5):1258‐65.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. Vol. 2, Lyon, France: IARC Press, 2008.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8(16):www.trialsjournal.com/content.
Tilly H, Zelenetz A. Treatment of follicular lymphoma: current status. Leukemia & Lymphoma 2008;49 Suppl 1:7‐17.
Van Dalen EC, Van der Pal HJ, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database of Systematic Reviews 2009, Issue 4. [Art. No.: CD005006. DOI: 10.1002/14651858.CD005006.pub4]
Vidal L, Gafter‐Gvili A, Leibovici L, Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database of Systematic Reviews 2009, Issue 2. [Art. No.: CD006552. DOI: 10.1002/14651858.CD006552.pub2]
Vitolo U, Ferreri AJ, Montoto S. Follicular lymphomas. Critical Reviews in Oncology/Hematology 2008;66(3):248‐61.
Wendum D, Sebban C, Gaulard P, Coiffier B, Tilly H, Cazals D, et al. Follicular large‐cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B‐cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology 1997;15(4):1654‐63.
Williamson P, Tudur Smith C, Hutton JL, Marson AG. Aggregrate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine 2002;21:3337‐3351.
Wood L, Egger M, Gluud LL, Schulz KF, J?ni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ 2008 Mar 15;336(7644):601‐5.
